National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

lintuzumab
A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:HuG1-M195
HuG1-M195 monoclonal antibody
Hu-M195 monoclonal antibody
Abbreviations:MOAB HuG1-M195
MOAB HuM195



Previous:Liazal, licorice root extract, lidocaine, Lidothesin, Linomide
Next:Lioresal, liothyronine sodium, Lipiocis, Lipiodol, Lipitor

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov